Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
1–4
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
An appropriately signed and dated assent must be obtained from the parent/guardian of the subject.
Subjects with 1 to \<4 years of age at Visit 1.
Subjects who have been prescribed Flixotide 50 µg for a medically appropriate use for the first time will be included in this observational program; Flixotide 50 µg therapy should be in line with the approved dosing: 50 to100 µg twice daily; subjects should have the ability to inhale the doses via a pediatric spacer with a face mask appropriately; subjects who have been exposed to Flixotide 50 µg, 125 µg and 250 µg treatment previously will not be included.
The parent/guardian of the subject must provide reliable contact information which includes home phone or cell phone for the follow up visits.
The parent/guardian of the subject must have the ability to comply study procedures.
Specific information regarding warnings, precautions, contraindications, AEs, and other pertinent information on Flixotide 50 μg that may impact subject eligibility is provided in the approved product label.
You may not be if
\-
Clareo Health | Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
